Skip to main content
. 2023 Nov 20;2023(11):CD010966. doi: 10.1002/14651858.CD010966.pub4

35.5. Analysis.

35.5

Comparison 35: VX‐152 (200 mg twice daily) plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus placebo plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily), Outcome 5: Sweat chloride (absolute change from baseline)